Now showing items 21-40 of 3230

    • Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. 

      Qian, F; Rookus, MA; Leslie, G; Risch, HA; Greene, MH; Aalfs, CM; Adank, MA; Adlard, J; Agnarsson, BA; Ahmed, M; Aittomäki, K; Andrulis, IL; Arnold, N; Arun, BK; Ausems, MGEM; Azzollini, J; Barrowdale, D; Barwell, J; Benitez, J; Białkowska, K; Bonadona, V; Borde, J; Borg, A; Bradbury, AR; Brunet, J; Buys, SS; Caldés, T; Caligo, MA; Campbell, I; Carter, J; Chiquette, J; Chung, WK; Claes, KBM; Collée, JM; Collonge-Rame, M-A; Couch, FJ; Daly, MB; Delnatte, C; Diez, O; Domchek, SM; Dorfling, CM; Eason, J; Easton, DF; Eeles, R; Engel, C; Evans, DG; Faivre, L; Feliubadaló, L; Foretova, L; Friedman, E; Frost, D; Ganz, PA; Garber, J; Garcia-Barberan, V; Gehrig, A; Glendon, G; Godwin, AK; Gómez Garcia, EB; Hamann, U; Hauke, J; Hopper, JL; Hulick, PJ; Imyanitov, EN; Isaacs, C; Izatt, L; Jakubowska, A; Janavicius, R; John, EM; Karlan, BY; Kets, CM; Laitman, Y; Lázaro, C; Leroux, D; Lester, J; Lesueur, F; Loud, JT; Lubiński, J; Łukomska, A; McGuffog, L; Mebirouk, N; Meijers-Heijboer, HEJ; Meindl, A; Miller, A; Montagna, M; Mooij, TM; Mouret-Fourme, E; Nathanson, KL; Nehoray, B; Neuhausen, SL; Nevanlinna, H; Nielsen, FC; Offit, K; Olah, E; Ong, K-R; Oosterwijk, JC; Ottini, L; Parsons, MT; Peterlongo, P; Pfeiler, G; Pradhan, N; Radice, P; Ramus, SJ; Rantala, J; Rennert, G; Robson, M; Rodriguez, GC; Salani, R; Scheuner, MT; Schmutzler, RK; Shah, PD; Side, LE; Simard, J; Singer, CF; Steinemann, D; Stoppa-Lyonnet, D; Tan, YY; Teixeira, MR; Terry, MB; Thomassen, M; Tischkowitz, M; Tognazzo, S; Toland, AE; Tung, N; van Asperen, CJ; van Engelen, K; van Rensburg, EJ; Venat-Bouvet, L; Vierstraete, J; Wagner, G; Walker, L; Weitzel, JN; Yannoukakos, D; KConFab Investigators; HEBON Investigators; GEMO Study Collaborators; EMBRACE Collaborators; Antoniou, AC; Goldgar, DE; Olopade, OI; Chenevix-Trench, G; Rebbeck, TR; Huo, D; CIMBA (2019-07)
      BACKGROUND: Height and body mass index (BMI) are associated with higher ovarian cancer risk in the general population, but whether such associations exist among BRCA1/2 mutation carriers is unknown. METHODS: We applied a ...
    • Runs of homozygosity and testicular cancer risk. 

      Loveday, C; Sud, A; Litchfield, K; Levy, M; Holroyd, A; Broderick, P; Kote-Jarai, Z; Dunning, AM; Muir, K; Peto, J; Eeles, R; Easton, DF; Dudakia, D; Orr, N; Pashayan, N; UK Testicular Cancer Collaboration; PRACTICAL Consortium; Reid, A; Huddart, RA; Houlston, RS; Turnbull, C (2019-07)
      BACKGROUND: Testicular germ cell tumour (TGCT) is highly heritable but > 50% of the genetic risk remains unexplained. Epidemiological observation of greater relative risk to brothers of men with TGCT compared to sons has ...
    • History of the Selective Autophagy Research: How Did It Begin and Where Does It Stand Today? 

      Kirkin, V (2019-05-11)
      Autophagy, self-eating, is a pivotal catabolic mechanism that ensures homeostasis and survival of the cell in the face of stressors as different as starvation, infection, or protein misfolding. The importance of the research ...
    • Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. 

      Rescigno, P; Lorente, D; Dolling, D; Ferraldeschi, R; Rodrigues, DN; Riisnaes, R; Miranda, S; Bianchini, D; Zafeiriou, Z; Sideris, S; Ferreira, A; Figueiredo, I; Sumanasuriya, S; Mateo, J; Perez-Lopez, R; Sharp, A; Tunariu, N; de Bono, JS (2018-05)
      Background: Loss of PTEN is a common genomic aberration in castration-resistant prostate cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing resistance to next-generation hormonal treatment (NGHT) ...
    • Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. 

      Sumanasuriya, S; Omlin, A; Armstrong, A; Attard, G; Chi, KN; Bevan, CL; Shibakawa, A; IJzerman, MJ; De Laere, B; Lolkema, M; Lorente, D; Luo, J; Mehra, N; Olmos, D; Scher, H; Soule, H; Stoecklein, NH; Terstappen, LWMM; Waugh, D; de Bono, JS (2018-06)
      CONTEXT: In advanced prostate cancer (PC), there is increasing investigation of circulating biomarkers, including quantitation and characterization of circulating tumour cells and cell-free nucleic acids, for therapeutic ...
    • CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. 

      Zimmermann, M; Murina, O; Reijns, MAM; Agathanggelou, A; Challis, R; Tarnauskaitė, Ž; Muir, M; Fluteau, A; Aregger, M; McEwan, A; Yuan, W; Clarke, M; Lambros, MB; Paneesha, S; Moss, P; Chandrashekhar, M; Angers, S; Moffat, J; Brunton, VG; Hart, T; de Bono, J; Stankovic, T; Jackson, AP; Durocher, D (2018-07)
      The observation that BRCA1- and BRCA2-deficient cells are sensitive to inhibitors of poly(ADP-ribose) polymerase (PARP) has spurred the development of cancer therapies that use these inhibitors to target deficiencies in ...
    • A decade of clinical development of PARP inhibitors in perspective. 

      Mateo, J; Lord, CJ; Serra, V; Tutt, A; Balmaña, J; Castroviejo-Bermejo, M; Cruz, C; Oaknin, A; Kaye, SB; de Bono, JS (2019-06-20)
      Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in different cancer types; these alterations can also induce ...
    • A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. 

      O'Brien, MER; Sarker, D; Bhosle, J; Thillai, K; Yap, TA; Uttenreuther-Fischer, M; Pemberton, K; Jin, X; Wiebe, S; de Bono, J; Spicer, J (2018-11)
      PURPOSE: Afatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor activity with chemotherapy. METHODS: As part of a phase I trial in patients with advanced solid tumors (NCT00809133; 3 + 3 ...
    • Surrogate endpoints in advanced sarcoma trials: a meta-analysis. 

      Savina, M; Litière, S; Italiano, A; Burzykowski, T; Bonnetain, F; Gourgou, S; Rondeau, V; Blay, J-Y; Cousin, S; Duffaud, F; Gelderblom, H; Gronchi, A; Judson, I; Le Cesne, A; Lorigan, P; Maurel, J; van der Graaf, W; Verweij, J; Mathoulin-Pélissier, S; Bellera, C (2018-10-02)
      Background: Alternative endpoints to overall survival (OS) are frequently used to assess treatment efficacy in randomized controlled trials (RCT). Their properties in terms of surrogate outcomes for OS need to be assessed. ...
    • Mutational processes contributing to the development of multiple myeloma. 

      Hoang, PH; Cornish, AJ; Dobbins, SE; Kaiser, M; Houlston, RS (2019-08-06)
      To gain insight into multiple myeloma (MM) tumorigenesis, we analyzed the mutational signatures in 874 whole-exome and 850 whole-genome data from the CoMMpass Study. We identified that coding and non-coding regions are ...
    • Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. 

      Cesne, AL; Bauer, S; Demetri, GD; Han, G; Dezzani, L; Ahmad, Q; Blay, J-Y; Judson, I; Schöffski, P; Aglietta, M; Hohenberger, P; Gelderblom, H (2019-08-13)
      BACKGROUND: PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advanced soft tissue sarcomas (aSTS). We performed retrospective subgroup analyses to explore potential relationships between ...
    • Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes. 

      Went, M; Kinnersley, B; Sud, A; Johnson, DC; Weinhold, N; Försti, A; van Duin, M; Orlando, G; Mitchell, JS; Kuiper, R; Walker, BA; Gregory, WM; Hoffmann, P; Jackson, GH; Nöthen, MM; da Silva Filho, MI; Thomsen, H; Broyl, A; Davies, FE; Thorsteinsdottir, U; Hansson, M; Kaiser, M; Sonneveld, P; Goldschmidt, H; Stefansson, K; Hemminki, K; Nilsson, B; Morgan, GJ; Houlston, RS (2019-08-20)
      BACKGROUND: While genome-wide association studies (GWAS) of multiple myeloma (MM) have identified variants at 23 regions influencing risk, the genes underlying these associations are largely unknown. To identify candidate ...
    • Real-time intrafraction motion monitoring in external beam radiotherapy. 

      Bertholet, J; Knopf, A; Eiben, B; McClelland, J; Grimwood, A; Harris, E; Menten, M; Poulsen, P; Nguyen, DT; Keall, P; Oelfke, U (2019-08-07)
      Radiotherapy (RT) aims to deliver a spatially conformal dose of radiation to tumours while maximizing the dose sparing to healthy tissues. However, the internal patient anatomy is constantly moving due to respiratory, ...
    • Acquired genetic events and NF1 mutations in advanced breast cancer 

      Pearson, A; Proszek, P; Pascual, J; Fribbens, C; Shamsher, M; Kingston, B; O'Leary, B; Herrera-Abreu, M; Cutts, R; Garcia-Murillas, I; Bye, H; Walker, B; Gonzalez, D; Yuan, L; Jamal, S; Hubank, M; Lopez-Knowles, E; Schuster, E; Dowsett, M; Osin, P; Nerurkar, A; Parton, M; Okines, A; Johnston, S; Ring, A; Turner, N
    • Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. 

      Loriot, Y; Necchi, A; Park, SH; Garcia-Donas, J; Huddart, R; Burgess, E; Fleming, M; Rezazadeh, A; Mellado, B; Varlamov, S; Joshi, M; Duran, I; Tagawa, ST; Zakharia, Y; Zhong, B; Stuyckens, K; Santiago-Walker, A; De Porre, P; O'Hagan, A; Avadhani, A; Siefker-Radtke, AO; BLC2001 Study Group (2019-07-25)
      BACKGROUND: Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a tyrosine kinase ...
    • Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial. 

      Hrebien, S; Citi, V; Garcia-Murillas, I; Cutts, R; Fenwick, K; Kozarewa, I; McEwen, R; Ratnayake, J; Maudsley, R; Carr, TH; de Bruin, EC; Schiavon, G; Oliveira, M; Turner, NC (2019-03-12)
      BACKGROUND: Dynamic changes in circulating tumour DNA (ctDNA) levels may predict long-term outcome. We utilised samples from a phase I/II randomised trial (BEECH) to assess ctDNA dynamics as a surrogate for progression ...
    • Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk. 

      Wu, L; Shu, X; Bao, J; Guo, X; Kote-Jarai, Z; Haiman, CA; Eeles, RA; Zheng, W; PRACTICAL, CRUK, BPC3, CAPS, PEGASUS Consortia (2019-09-15)
      Several blood protein biomarkers have been associated with prostate cancer risk. However, most studies assessed only a small number of biomarkers and/or included a small sample size. To identify novel protein biomarkers ...
    • Identification of single nucleotide variants using position-specific error estimation in deep sequencing data 

      Kleftogiannis, D; Punta, M; Jayaram, A; Sandhu, S; Wong, SQ; Gasi Tandefelt, D; Conteduca, V; Wetterskog, D; Attard, G; Lise, S
      <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Targeted deep sequencing is a highly effective technology to identify known and novel single nucleotide variants (SNVs) with many ...
    • Identification of single nucleotide variants using position-specific error estimation in deep sequencing data. 

      Kleftogiannis, D; Punta, M; Jayaram, A; Sandhu, S; Wong, SQ; Gasi Tandefelt, D; Conteduca, V; Wetterskog, D; Attard, G; Lise, S (2019-08-02)
      BACKGROUND: Targeted deep sequencing is a highly effective technology to identify known and novel single nucleotide variants (SNVs) with many applications in translational medicine, disease monitoring and cancer profiling. ...
    • Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. 

      De Bleser, E; Jereczek-Fossa, BA; Pasquier, D; Zilli, T; Van As, N; Siva, S; Fodor, A; Dirix, P; Gomez-Iturriaga, A; Trippa, F; Detti, B; Ingrosso, G; Triggiani, L; Bruni, A; Alongi, F; Reynders, D; De Meerleer, G; Surgo, A; Loukili, K; Miralbell, R; Silva, P; Chander, S; Di Muzio, NG; Maranzano, E; Francolini, G; Lancia, A; Tree, A; Deantoni, CL; Ponti, E; Marvaso, G; Goetghebeur, E; Ost, P (2019-07-19)
      BACKGROUND: Stereotactic body radiotherapy (SBRT) and elective nodal radiotherapy (ENRT) are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer (PC); however, comparative data are still ...